AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7762464 — intervention group
Group type: EXPERIMENTAL
Intervention: Eversion detection in older subjects
Number of subjects: 36
Study 7762464 — intervention group
Group type: COMPARATOR
Intervention: Eversion detection in younger subjects
Number of subjects: 36
Study 7762464 — intervention group
Group type: EXPERIMENTAL
Intervention: Unipedal stance
Number of subjects: 36
Study 7762464 — intervention group
Group type: EXPERIMENTAL
Intervention: Velocity increase from 2 to 200 degrees/s
Number of subjects: 36
Study 7762464 — intervention group
Group type: EXPERIMENTAL
Intervention: Threshold for sensing rotation in weight-bearing ankle
Number of subjects: 36
Study 1964728 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg of beta-carotene daily for four weeks
Number of subjects: 15
Study 1964728 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg of beta-carotene daily for four weeks
Number of subjects: 15
Study 26516 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg mequitazine daily for 14 days
Number of subjects: 48
Study 26516 — intervention group
Group type: COMPARATOR
Intervention: 24 mg brompheniramine daily for 14 days
Number of subjects: 48
Study 31954132 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold snare piecemeal endoscopic mucosal resection (CSP‐EMR)
Number of subjects: 186
Study 31162128 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine intervention via SMS text messages (every other week or weekly)
Number of subjects: 348
Study 31162128 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 348
Study 28679686 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 984
Study 28679686 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 984
Study 25841624 — intervention group
Group type: EXPERIMENTAL
Intervention: Charged Particle Therapy (CPT)
Number of subjects: 184
Study 25841624 — intervention group
Group type: COMPARATOR
Intervention: Iodine-125 Plaque Therapy
Number of subjects: 184
Study 23712578 — intervention group
Group type: EXPERIMENTAL
Intervention: Miniarc single-incision sling
Number of subjects: 71
Study 23712578 — intervention group
Group type: COMPARATOR
Intervention: Advantage retropubic mid-urethral sling
Number of subjects: 71
Study 21112655 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-IFN
Number of subjects: 200
Study 21112655 — intervention group
Group type: COMPARATOR
Intervention: ETV
Number of subjects: 200
Study 19951446 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised resistance/aerobic exercise
Number of subjects: 370
Study 19951446 — intervention group
Group type: COMPARATOR
Intervention: Printed material comprising general physical activity recommendations
Number of subjects: 370
Study 17309740 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9% saline
Number of subjects: 140
Study 17309740 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% NaOCl
Number of subjects: 140
Study 17309740 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% H(2)O(2)
Number of subjects: 140
Study 17309740 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine
Number of subjects: 140
Study 17309740 — intervention group
Group type: EXPERIMENTAL
Intervention: 17% EDTA
Number of subjects: 140
Study 17309740 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultracaine D‐S
Number of subjects: 140
Study 17309740 — intervention group
Group type: COMPARATOR
Intervention: absence of an irrigating solution (control)
Number of subjects: 140
Study 15829447 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based (HB) physical activity program, 3 times per week for 6 months
Number of subjects: 37
Study 15829447 — intervention group
Group type: COMPARATOR
Intervention: Control (CTL) condition, usual pattern of physical activity
Number of subjects: 37
Study 15829447 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based (HB) physical activity program
Number of subjects: 37
Study 15829447 — intervention group
Group type: COMPARATOR
Intervention: Control (CTL) condition
Number of subjects: 37
Study 11560298 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus GG, 20 x 10(9) CFU/d
Number of subjects: 302
Study 11560298 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 302
Study 9692126 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micrograms of salbutamol inhaled from the MDPI
Number of subjects: 26
Study 9692126 — intervention group
Group type: COMPARATOR
Intervention: 100 micrograms of salbutamol inhaled from the pMDI + S
Number of subjects: 26
Study 9692126 — intervention group
Group type: COMPARATOR
Intervention: Placebo from the MDPI
Number of subjects: 26
Study 8147091 — intervention group
Group type: EXPERIMENTAL
Intervention: R32Tox‐A vaccine
Number of subjects: 199
Study 8147091 — intervention group
Group type: COMPARATOR
Intervention: Control vaccine
Number of subjects: 199
Study 3062536 — intervention group
Group type: EXPERIMENTAL
Intervention: Apraclonidine hydrochloride (ALO 2145)
Number of subjects: 20
Study 3062536 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 20
Study 30478457 — intervention group
Group type: EXPERIMENTAL
Intervention: Macintosh laryngoscope
Number of subjects: 108
Study 28145964 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted rectus sheath block (LRSB) with 10 mL of 0.25% levobupivacaine at 4 sites after umbilical wound closure
Number of subjects: 38
Study 28145964 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted rectus sheath block (LRSB)
Number of subjects: 38
Study 28145964 — intervention group
Group type: COMPARATOR
Intervention: Control group with conventional postoperative pain management
Number of subjects: 38
Study 26340010 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate loading
Number of subjects: 36
Study 26340010 — intervention group
Group type: COMPARATOR
Intervention: Conventional loading (Control)
Number of subjects: 36
Study 24601127 — intervention group
Group type: EXPERIMENTAL
Intervention: VUS-guided peripheral intravenous catheter insertion
Number of subjects: 335
Study 24601127 — intervention group
Group type: COMPARATOR
Intervention: Traditional puncture guided by clinical assessment (Control Group)
Number of subjects: 335
Study 20004877 — intervention group
Group type: EXPERIMENTAL
Intervention: Proclear 1-Day
Number of subjects: 41
Study 20004877 — intervention group
Group type: COMPARATOR
Intervention: Focus Dailies with AquaRelease
Number of subjects: 41
Study 18437130 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol 5 mg daily for 4 weeks
Number of subjects: 40
Study 18437130 — intervention group
Group type: COMPARATOR
Intervention: Atenolol 50 mg daily for 4 weeks
Number of subjects: 40
Study 16169315 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban (group 1)
Number of subjects: 300
Study 16169315 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel plus provisional abciximab (group 2)
Number of subjects: 300
Study 12576946 — intervention group
Group type: EXPERIMENTAL
Intervention: MAB-T88 (300 mg intravenous infusion over 30 mins)
Number of subjects: 826
Study 12576946 — intervention group
Group type: COMPARATOR
Intervention: Placebo (albumin)
Number of subjects: 826
Study 10593636 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 80
Study 10593636 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 80
Study 10593636 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 10593636 — intervention group
Group type: EXPERIMENTAL
Intervention: High baseline daily stress
Number of subjects: 80
Study 10593636 — intervention group
Group type: EXPERIMENTAL
Intervention: High baseline hostility
Number of subjects: 80
Study 9363264 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinfamide at doses of 4.3 mg/kg b.i.d. in children and 100 mg t.i.d. in adults for one day
Number of subjects: 110
Study 9363264 — intervention group
Group type: COMPARATOR
Intervention: Etiamide at doses of 200 mg t.i.d. in children and 500 mg b.i.d. in adults for three days
Number of subjects: 110
Study 1767803 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoroquinolones
Number of subjects: 0
Study 6445816 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 percent solution of erythromycin
Number of subjects: 26
Study 6445816 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 26
Study 6445816 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 percent solution of erythromycin (continued therapy)
Number of subjects: 26
Study 31535314 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning super learner model
Number of subjects: 24178
Study 31535314 — intervention group
Group type: COMPARATOR
Intervention: Logistic regression
Number of subjects: 24178
Study 31535314 — intervention group
Group type: EXPERIMENTAL
Intervention: Super learner model
Number of subjects: 24178
Study 31386114 — intervention group
Group type: EXPERIMENTAL
Intervention: Low free sugar diet
Number of subjects: 0
Study 31386114 — intervention group
Group type: COMPARATOR
Intervention: Usual diet
Number of subjects: 0
Study 28319947 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin (0.75 µg)
Number of subjects: 49
Study 28319947 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 25886540 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual lifestyle counseling (n=6091)
Number of subjects: 6091
Study 25886540 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=3324)
Number of subjects: 6091
Study 24014906 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 88
Study 24014906 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 88
Study 21196831 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium cast in a pressure‐differential device (Cyclarc II, Morita)
Number of subjects: 30
Study 21196831 — intervention group
Group type: COMPARATOR
Intervention: Cobalt‐chromium cast in a centrifugal machine (TS1, Degussa‐Hüls)
Number of subjects: 30
Study 19436724 — intervention group
Group type: EXPERIMENTAL
Intervention: Dementia participants
Number of subjects: 179
Study 19436724 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosis of Lewy body disorder
Number of subjects: 179
Study 19436724 — intervention group
Group type: EXPERIMENTAL
Intervention: History of falls in the preceding 12 months
Number of subjects: 179
Study 19436724 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic orthostatic hypotension
Number of subjects: 179
Study 19436724 — intervention group
Group type: EXPERIMENTAL
Intervention: Autonomic symptom score
Number of subjects: 179
Study 19436724 — intervention group
Group type: EXPERIMENTAL
Intervention: Cornell depression score
Number of subjects: 179
Study 19436724 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of physical activity
Number of subjects: 179
Study 16426289 — intervention group
Group type: EXPERIMENTAL
Intervention: Cream product preserved with diazolidinyl urea at varying concentrations
Number of subjects: 0
Study 15296364 — intervention group
Group type: EXPERIMENTAL
Intervention: Sesamoid mobilization, flexor hallucis strengthening exercises, and gait training
Number of subjects: 20
Study 15296364 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (whirlpool, ultrasound, first MPJ mobilizations, calf and hamstring stretching, marble pick-up exercise, cold packs, and electrical stimulation)
Number of subjects: 20
Study 11367875 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil plus E. coli extract (LC-Extract)
Number of subjects: 164
Study 11367875 — intervention group
Group type: COMPARATOR
Intervention: 5-fluorouracil plus placebo
Number of subjects: 164
Study 9431482 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthracycline-naive patients
Number of subjects: 115
Study 9431482 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthracycline-treated patients
Number of subjects: 115
Study 9431482 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 115
Study 8055499 — intervention group
Group type: EXPERIMENTAL
Intervention: INTERPLAK Home Plaque‐Removal Instrument
Number of subjects: 30
Study 8055499 — intervention group
Group type: COMPARATOR
Intervention: Manual brushing and flossing
Number of subjects: 30
Study 3563413 — intervention group
Group type: EXPERIMENTAL
Intervention: Jejunoileal bypass with a 1:3 ratio
Number of subjects: 35
Study 3563413 — intervention group
Group type: EXPERIMENTAL
Intervention: Jejunoileal bypass with a 3:1 ratio
Number of subjects: 35
Study 3563413 — intervention group
Group type: EXPERIMENTAL
Intervention: Jejunoileal bypass with a long ileal segment (37.5 cm)
Number of subjects: 35
Study 3563413 — intervention group
Group type: COMPARATOR
Intervention: Jejunoileal bypass with a short ileal segment (12.5 cm)
Number of subjects: 35
Study 3563413 — intervention group
Group type: COMPARATOR
Intervention: Unoperated patients
Number of subjects: 35
Study 30196301 — intervention group
Group type: EXPERIMENTAL
Intervention: IV RetacritTM
Number of subjects: 432
Study 30196301 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care (IV Epogen®)
Number of subjects: 432
Study 25799211 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% Fluorometholon (FML®) after capsulotomy in diabetic patients (Group 1)
Number of subjects: 88
Study 25799211 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% Fluorometholon (FML®) after capsulotomy in non-diabetic patients (Group 3)
Number of subjects: 88
Study 25799211 — intervention group
Group type: COMPARATOR
Intervention: 0.5% ketorolac (Acular®) and 0.1% Fluorometholon (FML®) after capsulotomy in diabetic patients (Group 2)
Number of subjects: 88
Study 25799211 — intervention group
Group type: COMPARATOR
Intervention: 0.5% ketorolac (Acular®) and 0.1% Fluorometholon (FML®) after capsulotomy in non-diabetic patients (Group 4)
Number of subjects: 88
Study 24164587 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical antibiotic prophylaxis
Number of subjects: 1008
Study 24164587 — intervention group
Group type: COMPARATOR
Intervention: Standard systemic antibiotic prophylaxis
Number of subjects: 1008
Study 23377514 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin phosphate 1.2%/BPO 2.5% gel
Number of subjects: 2813
Study 23377514 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 2813
Study 20136458 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (100 mg/day)
Number of subjects: 14
Study 20136458 — intervention group
Group type: COMPARATOR
Intervention: Placebo (glucose)
Number of subjects: 14
Study 16710026 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa (DA) 200 microg every two weeks (Q2W)
Number of subjects: 1220
Study 16710026 — intervention group
Group type: COMPARATOR
Intervention: Epoetin alfa (EA) 40,000 units every week (QW)
Number of subjects: 1220
Study 16710026 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa (DA) Q2W and Epoetin alfa (EA) QW
Number of subjects: 1220
Study 15641864 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (0.5 to 8 mg daily for 8 weeks)
Number of subjects: 21
Study 15641864 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for 8 weeks)
Number of subjects: 21
Study 11504166 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol alone
Number of subjects: 0
Study 11504166 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol plus ACE inhibitor (enalapril)
Number of subjects: 0
Study 11504166 — intervention group
Group type: COMPARATOR
Intervention: ACE inhibitor alone
Number of subjects: 0
Study 9785089 — intervention group
Group type: EXPERIMENTAL
Intervention: Local injection of macrophages prepared from a blood unit
Number of subjects: 199
Study 9785089 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatments
Number of subjects: 199
Study 7963169 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine-supplemented parenteral nutrition
Number of subjects: 43
Study 7963169 — intervention group
Group type: COMPARATOR
Intervention: Standard parenteral nutrition
Number of subjects: 43
Study 3597168 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg/kg caffeine
Number of subjects: 20
Study 3597168 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg caffeine
Number of subjects: 20
Study 3597168 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30558152 — intervention group
Group type: EXPERIMENTAL
Intervention: C.H.A.M.P. Families intervention including eight group-based (parent-only) education sessions over 13-weeks, eight home-based activities, and two group-based (family) follow-up support sessions.
Number of subjects: 0
Study 26883201 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid leaflet
Number of subjects: 15844
Study 26883201 — intervention group
Group type: COMPARATOR
Intervention: Usual invitation letter (Control)
Number of subjects: 15844
Study 26883201 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous attendance for screening
Number of subjects: 15844
Study 26883201 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium household income
Number of subjects: 15844
Study 25539779 — intervention group
Group type: EXPERIMENTAL
Intervention: Community jury (n=12)
Number of subjects: 26
Study 25539779 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=14)
Number of subjects: 26
Study 22584763 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated identification with physician notification of modified systemic inflammatory response syndrome criteria
Number of subjects: 442
Study 22584763 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 442
Study 21077566 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant contact technique with marshmallow roller tip
Number of subjects: 17
Study 21077566 — intervention group
Group type: COMPARATOR
Intervention: Two-point touch technique with marshmallow tip
Number of subjects: 17
Study 18662495 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide before breakfast and dinner (BD)
Number of subjects: 377
Study 18662495 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide before lunch and dinner (LD)
Number of subjects: 377
Study 15820346 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (TPM)
Number of subjects: 41
Study 15820346 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiagabine (TGB)
Number of subjects: 41
Study 15327343 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy (3 blocks of single sessions over one year, 8 to 10 sessions)
Number of subjects: 20
Study 15327343 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 20
Study 11383098 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot packs
Number of subjects: 0
Study 11383098 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold packs
Number of subjects: 0
Study 11383098 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 9216364 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced nurse practitioner units
Number of subjects: 3
Study 9216364 — intervention group
Group type: COMPARATOR
Intervention: Units without advanced nurse practitioners
Number of subjects: 3
Study 9216364 — intervention group
Group type: EXPERIMENTAL
Intervention: All units
Number of subjects: 3
Study 7967359 — intervention group
Group type: EXPERIMENTAL
Intervention: Desferrioxamine (subcutaneous infusion 50 mg/kg/12 hr)
Number of subjects: 19
Study 7967359 — intervention group
Group type: EXPERIMENTAL
Intervention: Desferrioxamine (intravenous infusion 50 mg/kg/6 hr or 100 mg/kg/24 hr)
Number of subjects: 19
Study 7967359 — intervention group
Group type: EXPERIMENTAL
Intervention: Desferrioxamine (both subcutaneous and intravenous)
Number of subjects: 19
Study 3602281 — intervention group
Group type: EXPERIMENTAL
Intervention: Stressful movie
Number of subjects: 11
Study 3602281 — intervention group
Group type: COMPARATOR
Intervention: Neutral movie
Number of subjects: 11
Study 3602281 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-stress nights
Number of subjects: 11
Study 31622733 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab, 10 mg/kg intravenously every 2 weeks for up to 12 months
Number of subjects: 0
Study 31622733 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30701750 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote blood pressure monitoring
Number of subjects: 0
Study 30701750 — intervention group
Group type: COMPARATOR
Intervention: Common practice of monitoring
Number of subjects: 0
Study 27539685 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphate-buffered tirofiban (early phase, n=879)
Number of subjects: 3232
Study 27539685 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrate-buffered tirofiban (late phase, n=737)
Number of subjects: 3232
Study 27539685 — intervention group
Group type: COMPARATOR
Intervention: Combined definition of thrombocytopenia (tirofiban vs. UFH)
Number of subjects: 3232
Study 27539685 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombocytopenia
Number of subjects: 3232
Study 27539685 — intervention group
Group type: COMPARATOR
Intervention: Phosphate-buffered tirofiban
Number of subjects: 3232
Study 25642585 — intervention group
Group type: EXPERIMENTAL
Intervention: Excluded participants in the Cyberball game
Number of subjects: 40
Study 25642585 — intervention group
Group type: COMPARATOR
Intervention: Included participants in the Cyberball game
Number of subjects: 40
Study 25642585 — intervention group
Group type: EXPERIMENTAL
Intervention: Excluded women
Number of subjects: 40
Study 25642585 — intervention group
Group type: COMPARATOR
Intervention: Included women and excluded men
Number of subjects: 40
Study 25642585 — intervention group
Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 40
Study 23040595 — intervention group
Group type: EXPERIMENTAL
Intervention: LVEF <40%
Number of subjects: 2430
Study 23040595 — intervention group
Group type: COMPARATOR
Intervention: LVEF ≥40%
Number of subjects: 2430
Study 23040595 — intervention group
Group type: EXPERIMENTAL
Intervention: LVEF <30%
Number of subjects: 2430
Study 23040595 — intervention group
Group type: EXPERIMENTAL
Intervention: LVEF 30% to 40%
Number of subjects: 2430
Study 23040595 — intervention group
Group type: EXPERIMENTAL
Intervention: LVEF 40% to 50%
Number of subjects: 2430
Study 23040595 — intervention group
Group type: EXPERIMENTAL
Intervention: LVEF 50% to 60%
Number of subjects: 2430
Study 23040595 — intervention group
Group type: EXPERIMENTAL
Intervention: LVEF ≥60%
Number of subjects: 2430
Study 21969495 — intervention group
Group type: EXPERIMENTAL
Intervention: P-CAP (perifosine 50 mg orally once daily, days 1 to 21 and CAP 825 mg/m2 orally twice daily, days 1 to 14)
Number of subjects: 38